Women's Clinical Trials & CROs Market Forecast to More Than Double by 2036 as Precision Medicine Reshapes Trial Design

A new 456-page report projects the global women's clinical trials and CRO market will grow from $9.9 billion in 2026 to $22.3 billion by 2036, as biomarker-driven research and decentralized trial models transform how women's health studies are designed and run.


Dublin, June 23, 2026 (GLOBE NEWSWIRE) -- The "Women's Clinical Trials & CROs Market Report 2026-2036" has been added to ResearchAndMarkets.com's offering.

The report's release comes as the women's health research landscape undergoes structural change. The global women's clinical trials and CRO market is valued at $9.9 billion in 2026 and forecast to reach $22.3 billion by 2036, growing at a CAGR of 8.5%. This trajectory is being driven by the rising prevalence of women-predominant conditions, expanding regulatory requirements for sex-specific safety evaluation, and growing adoption of precision medicine and biomarker-driven approaches across reproductive health, oncology, and hormonal disorder indications.

Technological change is accelerating this shift. As oncology, immunology, reproductive health, and endocrine research move toward molecularly defined patient subgroups, women's health trials increasingly depend on genomic assays, hormonal biomarkers, and pharmacogenomics that vary across female life stages. Decentralized trial models are reinforcing this trend: in 2025, Lindus Health launched hybrid women's health trials in oncology and reproductive medicine, leveraging more than 30 million electronic health records to double enrollment speed compared with traditional CRO approaches. In response, CROs are expanding integrated biomarker services, genomic data platforms, and adaptive trial operational systems to meet sponsor demand.

The market is also being reshaped by trade and policy dynamics. Because clinical trials depend on imported laboratory reagents, specialized medical devices, and biomanufacturing inputs, the sector carries exposure to tariff-related cost escalation, particularly in women's health, where pregnancy-safe diagnostic tools and hormone-testing kits often come from limited supplier bases. The report notes that U.S.-China tariff friction is already disrupting biospecimen flows and central laboratory operations, prompting some sponsors to shift recruitment and site activation toward CRO networks in India, Southeast Asia, and Europe.

Why This Report Matters

  • Size the opportunity with confidence; Revenue forecasts to 2036, segmented by trial phase, indication, study design, sponsor type, and service type, support investment and capacity planning across five regions and 23 leading national markets.
  • Benchmark against 19 leading companies; Detailed competitive profiles of IQVIA, ICON, Labcorp, Syneos Health, Charles River Laboratories, and other major players reveal financial positioning, product capabilities, and strategic outlook.
  • Navigate tariff and supply chain risk; Dedicated scenario modeling across V-shaped, U-shaped, and L-shaped recovery paths quantifies the impact of U.S. trade policy on trial costs and cross-border operations.
  • Track where innovation is concentrated; Coverage of biomarker integration, genomic data platforms, and decentralized trial execution highlights where competitive advantage is being built.
  • Plan regulatory and operational strategy; Analysis of sex-specific safety evaluation requirements and patient recruitment infrastructure supports compliance and trial design decisions.

For pharmaceutical sponsors, CROs, and investors, this combination of accelerating biomarker-driven demand and rising operational complexity from tariff exposure makes competitive positioning more consequential than ever. The report's analysis of how companies including Pfizer, Novartis, Merck, Johnson & Johnson, and WuXi AppTec are adapting their capabilities gives stakeholders a basis for identifying where outsourcing opportunities and operational risk are converging across the forecast period.

The full report, "Women's Clinical Trials & CROs Market Report 2026-2036," is available now in PDF format, with bespoke intelligence and customization options also offered by the publisher.

Companies Featured

  • Amgen
  • AstraZeneca
  • Bayer
  • Charles River Laboratories
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • ICON Plc
  • IQVIA
  • Johnson & Johnson
  • Labcorp
  • Lilly USA, LLC
  • Medpace
  • Medtronic
  • Merck & Co
  • Novartis AG.
  • Pfizer Inc
  • Syneos Health
  • Thermo Fisher Scientific
  • WuXi AppTec
  • AbbVie
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Careggi University Hospital
  • Charles River Laboratories
  • Daewon Pharmaceutical
  • Gilead Sciences
  • Gynica
  • Halda Therapeutics
  • Intra-Cellular Therapies
  • IQVIA
  • Mural Health
  • Medpace, Inc.
  • Medtronic
  • Merck & Co., Inc.
  • Mural Health
  • Naive / Flagship ecosystem (Flagship)
  • NVIDIA (collaboration partner)
  • Novartis AG
  • Oracle (collaboration partner)
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd)
  • Shigella vaccine / Bharat Biotech (licensee mention)
  • Syneos Health
  • TiumBio
  • Thermo Fisher Scientific
  • Verona Pharma
  • WuXi AppTec
  • Labcorp / Covance
  • Lilly USA, LLC
  • ICON Plc.
  • Johnson & Johnson (J&J)
  • amfAR (TREAT Asia) (The Foundation for AIDS Research)
  • APGOT (Asia Pacific Gynecologic Oncology Trials Group)
  • COFEPRIS
  • CONBIOETICA (Mexico National Bioethics Commission)
  • French Ministry of Health
  • MHRA (Medicines and Healthcare products Regulatory Agency, UK)
  • NCI (National Cancer Institute)
  • NMPA (National Medical Products Administration, China)
  • NIH ORWH (Office of Research on Women's Health)
  • University of Arizona Health Sciences (partner institution)
  • WHO (World Health Organization)

For more information about this report visit https://www.researchandmarkets.com/r/9gxczn

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data

GlobeNewswire

Recommended Reading